Clik here to view.
KEI welcomes the Gilead HCV licenses, as a step to expand access to...
Source: KEI 16 Sep 2014 Today Gilead announced it will provide seven generic drug manufacturers licenses to make and sell two drugs that are used in combination to treat the Hepatitis C Virus (HCV) in...
View ArticleClik here to view.
Clik here to view.
MSF Access Campaign response to Gilead’s deal with generic companies for...
Source: MSF Access Campaign 16 Sep 2014 On 15 September, Gilead Sciences is expected to announce agreements with a handful of Indian pharmaceutical manufacturers to produce and sell generic versions of...
View ArticleClik here to view.
Statement of Civil Society Organizations in Thailand
Voluntary License on Sofosbuvir and Ledipasvir between Gilead Sciences Limited and Generic-medicine Manufacturers in India September 16, 2014 Civil society organizations working on access to HIV and...
View ArticleClik here to view.
Silent protest by DNP+ and IDUF at Gilead’s Press Conference
15 Sep 2014, New Delhi Delhi Network of Positive People (DNP+) and Indian Drug User Forum (IDUF) organized a silent protest at Gilead Presser held at Hotel Taj Palace where Gilead made an announcement...
View ArticleClik here to view.
Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others
(Reuters) – 15, Sep 2014-U.S. drugmaker Gilead Sciences Inc (GILD.O) has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill...
View ArticleClik here to view.
Gilead to raise price for new hepatitis C drug above $84,000
September 12, 2014 Source: Reuters The next generation version of Gilead Sciences Inc’s $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive....
View ArticleClik here to view.
Breaking News: Gilead’s patent application for Sofosbuvir rejected in India
Gilead’s patent application for base compound of Sofosbuvir pending in Delhi Patent Office was rejected by Patent Controller General of India. See the decision here. This decision will pave the way for...
View ArticleClik here to view.
Gilead denied patent for hepatitis C drug sofosbuvir in India
Source: MSF Access Campaign 14 January, 2015 – The Indian Patent Controller has today rejected one of Gilead’s key patent applications which covered the drug sofosbuvir, used to treat hepatitis C...
View ArticleClik here to view.
MSF: Barriers to access and scale up of hepatitis C (HCV) treatment: Gilead’s...
Source: MSF Access Campaign 15 Jan 2014 The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began introducing hepatitis C (HCV) treatment to...
View Article
